Semax and Selank: Neuropeptide Research in Cognitive and Anxiety Models

Overview

Semax and Selank are two synthetic neuropeptides developed in Russia that have been studied in cognitive function and anxiety models. Both have been used clinically in Russia and have a more developed evidence base than many research peptides. This article reviews the published research on each compound.

Semax: ACTH Analogue with Neuroprotective Properties

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that is an analogue of the ACTH(4-10) fragment. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been used clinically in Russia since the 1990s for stroke recovery and cognitive enhancement.

Mechanism: Semax's mechanisms of action include: - Upregulation of BDNF (Brain-Derived Neurotrophic Factor) and its receptor TrkB in the hippocampus [1] - Modulation of dopaminergic and serotonergic neurotransmission - Neuroprotective effects in ischemia models through reduction of oxidative stress - Enhancement of memory consolidation in animal models

Published evidence: - Dolotov et al. (2006) demonstrated that Semax significantly increased BDNF and TrkB mRNA expression in the rat hippocampus, providing a molecular basis for its observed cognitive effects [1] - Mironova et al. (2016) reviewed clinical studies of Semax in ischemic stroke, reporting improvements in neurological outcomes in Russian clinical trials [2] - Animal studies in rodent models of ischemia consistently show neuroprotective effects with Semax administration

Administration: Semax is typically administered intranasally in research and clinical settings, as intranasal delivery allows direct access to the CNS via the olfactory pathway.

Selank: Tuftsin Analogue with Anxiolytic Properties

Selank is a synthetic hexapeptide (Thr-Lys-Pro-Arg-Pro-Gly) that is an analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of IgG. Selank was developed at the same institute as Semax and has been studied primarily in anxiety and stress models.

Mechanism: Selank's mechanisms include: - Modulation of GABAergic neurotransmission (similar to benzodiazepines, but without dependence potential in animal models) - Upregulation of BDNF expression - Modulation of IL-6 and other cytokines - Enhancement of enkephalin stability (reducing degradation of endogenous opioid peptides)

Published evidence: - Semenova et al. (2010) demonstrated anxiolytic effects of Selank in rodent models comparable to diazepam, without sedation or motor impairment [3] - Zozulya et al. (2014) reviewed the clinical development of Selank, noting its use in Russian clinical practice for anxiety disorders [4] - Studies show Selank modulates IL-6 expression, suggesting potential applications in neuroinflammation research

Comparison

| Parameter | Semax | Selank | |---|---|---| | Origin | ACTH(4-10) analogue | Tuftsin analogue | | Primary research area | Neuroprotection, cognition | Anxiety, stress response | | Key mechanism | BDNF upregulation, neuroprotection | GABAergic modulation, anxiolysis | | Administration | Intranasal | Intranasal | | Clinical use (Russia) | Stroke recovery, cognitive enhancement | Anxiety disorders |

Research Applications

Semax is appropriate for research models studying: - Neuroprotection in ischemia models - BDNF-mediated cognitive effects - Stroke recovery mechanisms

Selank is appropriate for research models studying: - Anxiety and stress response mechanisms - GABAergic modulation without sedation - Neuroinflammation and cytokine modulation

Conclusion

Semax and Selank are among the better-characterized research neuropeptides, with a more developed evidence base than most compounds in this category due to their clinical use in Russia. Researchers studying cognitive function, neuroprotection, or anxiety mechanisms may find both compounds useful research tools.

For research use only. Not for human or animal consumption.

References

1. Dolotov, O.V., et al. (2006). Semax, an analogue of ACTH(4-7), regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60.
2. Mironova, O.P., et al. (2016). Semax in the treatment of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova, 116(3), 49–54.
3. Semenova, T.P., et al. (2010). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Eksperimental'naia i Klinicheskaia Farmakologiia, 73(8), 2–5.
4. Zozulya, A.A., et al. (2014). The discovery and development of selank as an anti-anxiety drug. Expert Opinion on Drug Discovery, 9(9), 1131–1142.